Roth Capital raised the firm’s price target on CapsoVision (CV) to $11 from $7 and keeps a Buy rating on the shares after its Q4 pre-announcement and the closing of a $14M private placement. Proceeds from the financing are expected to support general corporate purposes, including R&D, sales and marketing, and working capital, with a focus on advancing key pipeline programs and AI capabilities, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CV:
- CV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- CapsoVision jumps over 20% after announcing preliminary Q4 revenue
- CapsoVision price target raised to $11 from $7 at Roth Capital
- CapsoVision Raises Capital and Refocuses Colon Capsule Strategy
- CapsoVision announces $14M private placement financing